Free Trial
OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Price, News & Analysis

Genmab A/S logo
$198.51 -6.49 (-3.17%)
As of 07/3/2025 12:46 PM Eastern

About Genmab A/S Stock (OTCMKTS:GNMSF)

Key Stats

Today's Range
$198.51
$203.00
50-Day Range
$188.80
$224.30
52-Week Range
$170.00
$292.80
Volume
24 shs
Average Volume
37 shs
Market Capitalization
$13.12 billion
P/E Ratio
11.26
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

GNMSF MarketRank™: 

Genmab A/S scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Genmab A/S.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 11.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.58.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 11.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Genmab A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.07% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 111.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 62.09%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.07% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 111.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 62.09%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Genmab A/S has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Genmab A/S this week, compared to 2 articles on an average week.
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

Genmab Completes Share Buy-back Program
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

GNMSF Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $207.38 at the start of the year. Since then, GNMSF shares have decreased by 4.3% and is now trading at $198.5060.

Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Thursday, May, 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The firm had revenue of $765.14 million for the quarter, compared to analyst estimates of $761.09 million. Genmab A/S had a trailing twelve-month return on equity of 19.23% and a net margin of 35.11%.

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:GNMSF
Employees
2,682
Year Founded
1999

Profitability

Trailing P/E Ratio
11.26
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.14 billion
Pretax Margin
40.96%

Debt

Sales & Book Value

Annual Sales
$3.12 billion
Cash Flow
$14.70 per share
Price / Cash Flow
13.50
Book Value
$80.53 per share
Price / Book
2.46

Miscellaneous

Free Float
65,057,000
Market Cap
$13.12 billion
Optionable
Not Optionable
Beta
0.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:GNMSF) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners